Identification of selective ion channel inhibitors represents a critical step for understanding the physiological role that these proteins play in native systems. In particular, voltage-gated potassium (K V 2) channels are widely expressed in tissues such as central nervous system, pancreas, and smooth muscle, but their particular contributions to cell function are not well understood. Although potent and selective peptide inhibitors of K V 2 channels have been characterized, selective small molecule K V 2 inhibitors have not been reported. For this purpose, highthroughput automated electrophysiology (IonWorks Quattro; Molecular Devices, Sunnyvale, CA) was used to screen a 200,000-compound mixture (10 compounds per sample) library for inhibitors of K V 2.1 channels. After deconvolution of 190 active samples, two compounds (A1 and B1) were identified that potently inhibit K V 2.1 and the other member of the K V 2 family, K V 2.2 (IC 50 , 0.1-0.2 ⌴), and that possess good selectivity over K V 1.2 (IC 50 Ͼ10 ⌴). Modeling studies suggest that these compounds possess a similar three-dimensional conformation. Compounds A1 and B1 are Ͼ10-fold selective over Na V channels and other K V channels and display weak activity (5-9 ⌴) on Ca V channels. The biological activity of compound A1 on native K V 2 channels was confirmed in electrophysiological recordings of rat insulinoma cells, which are known to express K V 2 channels. Medicinal chemistry efforts revealed a defined structure-activity relationship and led to the identification of two compounds (RY785 and RY796) without significant Ca V channel activity. Taken together, these newly identified channel inhibitors represent important tools for the study of K V 2 channels in biological systems.
Introduction
Voltage-gated potassium (K V ) channels open in response to membrane depolarization and are present in many cell types. In excitable cells, K V channels serve as the primary mechanism of repolarization of action potentials, whereas in nonexcitable cells, K V channels control the cell resting potential. Given the role of K V channels, it is not surprising that they regulate many fundamental physiological processes and are therefore considered important therapeutic targets for treatment of autoimmune, metabolic, neurological, and cardiovascular disorders, as well as cancer (Wulff et al., 2009) . Despite these facts, there has been limited success in the clinical development of therapeutic agents that target K V channels. One reason for this is that many of the small molecules identified to date lack true molecular selectivity across members of the K V and other ion channel families, which could significantly compromise their therapeutic index. The lack of ion channel selectivity seems to be due to binding of compounds to highly conserved regions across channels (Hanner et al., 1999 (Hanner et al., , 2001 Rolf et al., 2000; Decher et al., 2004 Decher et al., , 2006 Eldstrom et al., 2007; Karczewski et al., 2009; Zimin et al., 2010) . Another reason for the slow progress in drug development is the difficulty in screening large compound libraries with assays that measure channel function (i.e., K conduction) directly, although the development of automated elec-trophysiology platforms is beginning to address some of these issues (Dunlop et al., 2008) .
The K V 2 channel family consists of two members, K V 2.1 and K V 2.2. K V 2.1 is prominently expressed in the brain, notably in pyramidal neurons of the hippocampus and cortex, where it regulates excitability (Misonou et al., 2005) . In rodents, K V 2.1 channels are present in cardiac ventricular myocytes (Nerbonne and Kass, 2005) . K V 2.1 also regulates insulin secretion from the pancreatic ␤ cell (Jacobson et al., 2007) . K V 2.2 is expressed in brain (Hwang et al., 1992) , smooth muscle (Schmalz et al., 1998) , and somatostatin secreting ␦-cells of the pancreatic islet Wolf-Goldberg et al., 2006) ; however, little is known about the role of K V 2.2 channels in these tissues. The assessment of the roles of K V 2.1 and K V 2.2 channels in tissues where they are expressed, and the consequences of channel modulation in vivo, has been hampered by the lack of selective pharmacological tools. Gating modifier peptides highly selective for K V 2 channels have been identified in the venoms of tarantulas (for review, see Swartz, 2007) . However, the limited availability of these peptides has often hampered their use in the study of physiological systems. Highly selective, small-molecule inhibitors of K V 2 channels would be useful in this regard, but the reported number of these molecules is quite limited. For example, although the antiarrhythmics propafenone and flecainide seem to block K V 2.1 channels more potently than K V 1 channels (Rolf et al., 2000) , these compounds have actions on other channels as well.
.1]nonan-9-yl 4-chlorobenzoate (C-1), a besipirdine derivative, has been shown to have some selectivity for K V 2.1 channels over other K V channels (MacDonald et al., 2002) . Thus, there is a need for identifying novel and selective K V 2 inhibitors with which to investigate the role of these channels and develop their pharmacology.
The IonWorks Quattro automated electrophysiology instrument functions in a 384-well format that is well suited for screening compound libraries for activity on K V channels, and in a previous work, we reported on the development of a robust assay for K V 2.1 channels using this platform . In this study, we apply this assay to screen a 200,000-compound library for inhibitors of K V 2.1 channels. We report the discovery and optimization of two series of compounds with striking selectivity for K V 2 channels over other K V , and Ca V , and Na V channels. Cell Culture. hK V 2.1.CHO cells were maintained in minimal essential media ␣ with nucleosides supplemented with 10% certified fetal bovine serum, 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, 0.29 mg/ml L-glutamine, and 2 g/ml blasticidin S HCl. hK V 1.2.CHO cells were maintained in Iscove's modified Eagle's medium supplemented with 10% certified fetal bovine serum, 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, 0.29 mg/ml L-glutamine, 1ϫ hypoxanthine-thymidine supplement, and 0.5 mg/ml G418. hK V 2.1.CHO were grown in the presence of 10% CO 2 , whereas hK V 1.2.CHO cells were grown at 5% CO 2 . INS-1 cells were cultured as described previously (Hohmeier et al., 2000) .
Materials and Methods

Materials
Automated 384-Well Electrophysiology. K V 2.1 currents were recorded using the IonWorks Quattro system (Molecular Devices, Sunnyvale, CA) in population patch clamp mode as described previously . The standard voltage pulse protocol was a series of forty 100-ms pulses at a frequency of 5 Hz. The prepulse holding potential was Ϫ80 mV, and the steps were to ϩ50 mV. Currents were sampled at a rate of 1.25 kHz. After an initial read, compound (or vehicle) was added for ϳ3 min, and a second voltage train was applied. Ten point concentration dilution series were created by serially diluting a 2 mM DMSO stock 1:3 in DMSO. The upper final concentration applied to cells was 20 M. The final concentration of DMSO (1%) had no effect on control current recordings.
Conventional Patch Clamp Electrophysiology. Membrane currents were recorded at room temperature (23-25°C) using standard dialyzed, whole-cell voltage clamp techniques as described previously (Herrington et al., 2005 ). The internal solution was 100 mM potassium aspartate, 40 mM KCl, 10 mM EGTA, 10 mM HEPES, 4 mM MgATP, pH 7.2 with KOH. The external solution was 150 in mM NaCl, 4 in mM KCl, 1.8 mM CaCl 2 ,0.5 mM MgCl 2 , 10 mM HEPES, and 3 mM glucose, pH 7.4 with NaOH. Compounds were diluted in external solution from 10 to 20 mM stocks in DMSO. The final concentration of DMSO did not exceed 0.1%.
Results
A ϳ200,000-compound library was screened on hK V 2.1 channels stably expressed in CHO cells using the IonWorks Quattro 384-well automated electrophysiology platform. The details of this assay have been described previously . In brief, a 40-pulse train of voltage steps was applied at 5 Hz. This protocol is designed to detect usedependent block (i.e., greater inhibition of current at the 40th pulse compared with the 1st pulse). To maximize the throughput of the screen and to contain the cost of consumables, each compound well contained a mixture of 10 compounds. Initial studies revealed that a screening concentration of 1 ⌴ per compound (10 ⌴ total in the well) was optimal for achieving a modest hit rate. Higher screening concentrations produced too many active wells, presumably as a result of the additive effects of 10 compounds in each well. Figure 1A shows the number of active wells for the 56 384-well plates used in the screen. Using a cutoff of 40% inhibition at pulse 40, 7.8 Ϯ 0.6 active wells were detected per plate. From the primary screen of the library, 190 wells were selected for deconvolution, yielding 1894 compounds. These compounds were tested in isolation in two different K V 2.1 paradigms: IonWorks and a fluorescence assay measuring changes in membrane potential. Results from testing in IonWorks Quattro (in triplicate) and the resulting histogram are shown in Fig. 1B . Based on the 40% inhibition cutoff at pulse 40, 180 compounds were confirmed as active, yielding an overall hit rate for the IonWorks Quattro screen of approximately 0.1%.
Evaluation of the 1894 compounds at 4 ⌴ in the membrane potential assay (data not shown) identified 31 compounds that were chosen for retesting on K V 2.1 in the IonWorks assay. As an initial test for selectivity, the 31 compounds were tested in parallel on K V 1.2 using the same IonWorks assay protocol. Data from these experiments are illustrated in Fig. 1C , where the percentage inhibition of K V 2.1 (40th pulse) is plotted versus percentage inhibition of K V 1.2 (40th pulse). It is noteworthy that two compounds, identified by arrows, showed apparent selectivity for K V 2.1 over the K V 1.2 channel. The structures of these compounds (compounds A1 and B1) are shown in Fig. 1D . Superposition of three-dimensional conformations of A1 and B1 predicted reasonable overlap. Good overall overlap can be maintained by superimposing the center benzene ring of both A1 and B1 with the imidazole ring of A1 mapping onto the aniline amide of B1. This overlay also places the thiazole ring of A1 on top of the cyclopentane of B1.
The activities of A1 and B1 on K V 2.1 were re-confirmed by purification or re-synthesis of the compounds. Inspection of the recordings from the IonWorks assay revealed that the compounds are use-dependent inhibitors of K V 2.1 ( Fig. 2A,  top) . For compound A1, the potency was 10-fold higher at pulse 40 versus pulse 1 (pulse 40 IC 50 , 0.20 ⌴; pulse 1 IC 50 , 2.0 ⌴, n ϭ 4). The potency of compound B1 shifted similarly (pulse 40 IC 50 , 0.15 ⌴; pulse 1 IC 50 , 2.1 ⌴, n ϭ 4). Compound B1 was further resolved to its enantiomers by chiral high-performance liquid chromatography. The S-enantiomer [compound B1 (S)] and the R-enantiomer [compound B1 (R)] had similar potency on K V 2.1 (IC 50 , 0.15 and 0.20 ⌴, respectively). Further profiling showed that these compounds are equipotent inhibitors of K V 2.1 and K V 2.2 channels ( Table 1) .
The initial observation concerning the selectivity of these compounds for K V 2.1 over K V 1.2 channels was confirmed in detailed concentration-response measurements (Fig. 2B) . Both compounds displayed weak activity as inhibitors of K V 1.2 at either pulse 40 or pulse 1 (Fig. 2, Table 1 ). For example, compound A1 inhibited K V 1.2 at pulse 40 with an IC 50 of 12.1 ⌴ (n ϭ 3), which is 50-fold higher than the IC 50 for inhibition of K V 2.1.
The two K V 2.1 inhibitors were also tested on a variety of voltage-gated channels, using primarily functional assays. For comparison with other K V channels, the identical IonWorks electrophysiology assay of K V 2.1 was used to allow direct comparison with K V 2 channel data. Both compounds displayed weak activity on the K V channels K V 1.5 and K V 3.2. The compounds also displayed weak activity on the human ether-à -go-go-related gene channel (K V 11.1) based on a radioligand binding assay as well as on Na V and Ca V channels in functional assays. In general, compound B1 showed greater selectivity for K V 2 channels over other channels (average, 75-fold) compared with compound A1 (average, 35-fold). Compound B1 was screened on 163 additional targets in a panel of enzyme and radioligand binding assays (performed by MDS Pharma Services, King of Prussia, PA). This panel included 10 additional ion channel targets. At 10 ⌴, compound B1 displayed significant activity (Ͼ50% inhibition) on only three targets: adenosine receptor A3 (IC 50 , 0.84 ⌴, radioligand binding), 5-lipoxygenase (IC 50 , 2.0 ⌴, enzyme activity), and serotonin receptor 2B (IC 50 , 6.5 ⌴, radioligand binding).
Despite the selectivity of A1 and B1 for many ion channels, however, both compounds display moderate activity on Ca V 1.2 and Ca V 2.3 channels (Table 1) . Because functional block of Ca V channels will limit the utility of these compounds in the evaluation of certain physiological systems, medicinal chemistry efforts were aimed at identifying analogs of these compounds with reduced activity on Ca V channels. Two analogs were found that retained potency on K V 2 channels, but had much reduced activity on Ca V 2 channels. These compounds were termed RY785 and RY796 (Table 1) .
In initial structure-activity relationship studies, analogs of both A and B series were found to display similar structureactivity relationship at the corresponding overlapping regions, as shown in Table 2 . It is thus likely that the two compound series bind at overlapping sites on K V 2 channels. A stereochemical preference for binding to K V 2.1 was present in some analogs in the B series. For compound B2, the Senantiomer (RY796) is 5-fold more potent than the R-enantiomer. For the A series compounds, a stereochemical preference for K V 2.1 inhibition did not seem to exist. For example, RY785 is the first (fast) eluting enantiomer (IC 50 , 0.05 ⌴) from the chiral column separation of a racemic mixture. The slow eluting enantiomer was equally active as an inhibitor of K V 2.1 (IC 50 , 0.07 ⌴). Similar results were observed when the m-MeO group in RY785 was replaced with (Dai et al., 2008) . For all sodium channels, values are from fluorescence membrane potential-based assay (Felix et al., 2004) . Data for compound B1 on K V 2.1, K V 1.2, K V 1.5, and K V 3.2 were obtained using the racemic mixture; all other data were obtained using the pure S-enantiomer. Pure S-and R-enantiomers of compound B1 had equal potency on K V 2.1. o-chlorine (IC 50 , 0.12 and 0.14 ⌴ for inhibition of K V 2.1 by the enantiomers). Pancreatic ␤ cells are known to express K V 2 channels (for review, see MacDonald and Wheeler, 2003) . The rat insulinoma cell line INS-1 expresses both K V 2.1 and K V 2.2 channels (Su et al., 2001) . The majority of K V current in INS-1 cells probably arises from K V 2 channels, based on its sensitivity to the K V 2 gating modifier peptide GxTX-1E (Herrington, 2007 ). Thus, we tested the newly identified K V 2 inhibitors on the K V current in INS-1 cells. Compound A1 inhibited the majority of current in these cells (Fig. 3) , and inhibition seems to be reversible upon washing out the compound. Based on recordings from three cells, compound A1 blocked INS-1 K V current an average of 71% at 0.3 ⌴ and 84% at 3 ⌴ (n ϭ 2 per concentration), providing further evidence that the compounds identified by the automated electrophysiology screen are indeed inhibitors of native K V 2 channels.
Discussion
The aim of the present study was to identify novel inhibitors of K V 2 channels with improved selectivity over other available small molecule tools. We chose to use automated electrophysiology as the primary assay because it provides a direct measurement of channel activity and is the method best suited to identify compounds that interact with K V channels in a state-dependent manner. The IonWorks Quattro 384-well platform allowed sufficient throughput to screen a library of approximately 200,000 compounds. Despite the higher density format of IonWorks compared with other automated electrophysiology devices, we needed to test compounds in mixtures to maximize throughput and minimize consumable costs. This approach, however, did not allow a screening concentration higher than 1 ⌴ per compound (10 ⌴ total) to achieve manageable hit rates. Nevertheless, our data provide convincing evidence that this approach has utility for the screening of large compound libraries by automated electrophysiology. It is noteworthy that the use of a single instrument and voltage protocol allowed the unbiased measurement of selectivity of the newly identified K V 2 inhibitors across K V channel subtypes.
The successful identification of small molecules that specifically target K V 2 channels using automated electrophysiology suggests areas for future work. In addition, further studies with the K V 2 inhibitors concerning their site of interaction with the channel need to be pursued. These compounds may in fact represent a novel pharmacophore in K V 2 channels that should be exploited for designing new ion channel modulators. Few mapping studies of other K V 2 channel inhibitors exist. Flecainide and propafenone, two antiarrhythmics with broad ion channel activity, are micromolar K V 2.1 inhibitors with weaker potency on K V 1.2 (Rolf et al., 2000) . Flecainide and propafenone are thought to interact with residues at the interface of the P-helix of one subunit and the inner S6 helix of an adjacent subunit and to block ion permeation from within the central cavity (Madeja et al., 2003 (Madeja et al., , 2010 . Because the residues at the subunit interface are less conserved than those that line the inside of the central cavity, such a binding site may provide a degree of selectivity across families of channels. It is noteworthy that the molecules identified in this study are electroneutral, whereas flecainide and propafenone possess cationic groups. Zimin et al. (2010) proposed a mechanism for block of K V channels by electroneutral molecules. Thus, it will be interesting to determine the binding site(s) and mechanism of block of the K V 2 inhibitors identified in this study. The future identification of novel molecules specifically targeting distinct K V channels holds considerable promise for the discovery of therapeutics to treat a spectrum of diseases. Such agents, in addition to their selectivity for other ion channels, will need to be optimized for favorable pharmacokinetic and drug metabolism profiles, as well as other parameters, before they can be considered to enter clinical development. Medicinal chemistry efforts will be needed to determine whether the new classes of K V 2 inhibitors described in the present study can be modified to accomplish such a goal. In the meantime, these agents may prove to be useful to evaluate the role that K V 2 channels play in native tissues.
